Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coughing up for cough coup: Vernalis pulls it off again

This article was originally published in Scrip

Executive Summary

The remarkable thing about the UK firm Vernalis is how many times it has in its various incarnations been able to extract cash from shareholders without having delivered on its promises. This time, says CEO Ian Garland, is the last time. It has just announced a £68.5 million placing and open offer in which it has convinced both new and existing investors of the wisdom of establishing a North American commercial infrastructure through which to channel extended-release liquid prescription cough and cold products from its new partner, Tris Pharma.

You may also be interested in...



Vernalis Raises $58m To Close Potential Funding Gap

Slower than expected US sales of its first long-acting liquid cough-and-cold formulation, and improved visibility on its future US infrastructure costs, has prompted UK-based Vernalis to raise funds from existing investors to support further product launches and to reach the goal of sustainable profitability.

Big Pharma’s Aging Antibodies Cling To Their Crowns

The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?

Novartis To Pay $9.7bn For The Medicines Company

Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016226

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel